Mirae Asset Global Investments Co., Ltd. Arbutus Biopharma Corp Transaction History
Mirae Asset Global Investments Co., Ltd.
- $20 Billion
- Q2 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 5,634 shares of ABUS stock, worth $22,986. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,634Holding current value
$22,986% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ABUS
# of Institutions
137Shares Held
95.4MCall Options Held
3.44MPut Options Held
377K-
Morgan Stanley New York, NY21MShares$85.5 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY12.9MShares$52.5 Million30.08% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$47.1 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.57MShares$35 Million10.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.02MShares$28.7 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $612M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...